Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
150 participants
INTERVENTIONAL
2024-11-01
2027-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Analysis of Radiotherapeutic and Medical Procedures for the Prophylaxis of Heterotopic Ossifications
NCT06251349
A Prospective Randomized Controlled Trial on the Use of Bone Morphogenetic 7 (BMP-7) (OP-1®) and Demineralized Bone Matrix in Tibial Non-union
NCT00551941
Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting
NCT01429012
Comparison of Conservative and Operative Treatment of Jones Fracture
NCT04037540
Freeze-dried Bovine Hydroxyapatite/Secretome Composite for Bone Defects
NCT04980261
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of the study was to evaluate the effect of ossein-hydroxyapatite complex (Osteogenon) as an adjunctive treatment on the outcome of conservative and surgical fractures treatment via comprehensive clinical, radiological and biomechanical assessments. The investigators aimed to reject the null hypothesis of the absence of beneficial effect of ossein-hydroxyapatite complex on fractures treatment outcomes. This would fill the existing gap in the scientific literature and enable a more widespread use of Osteogenon in the treatment of fractures in many trauma centers.
Patients in the study group with fractures received an ossein-hydroxyapatite complex (830 milligram \[mg\] of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily.
The drug Osteogenon used in our study had been approved for fracture treatment. The study was conducted in accordance with the Declaration of Helsinki and all applicable laws and regulations. All patients had provided their written informed consent and were informed of a voluntary nature of their participation in this study.
Patients participating in the study, both in the study and control groups, had to meet the inclusion criteria. The randomization method used was to evenly recruit the study and control groups as patients who met the inclusion criteria were recruited. Randomization took into account the equal distribution of gender and age in both groups.
Patients from both the experimental and control groups received the same recommendations regarding rehabilitation and had the same clinical and radiological follow-up protocol.
The following clinical, biomechanical and radiological parameters were assessed in the study: the period of immobilization, rate of bone union, analgesic use at the beginning of treatment, analgesic use during the follow-up, time to achieving pain relief, pain in 100 millimeter \[mm\] Visual Analogue Scale (VAS), number of patients declaring pain relief, rate of complications, time to resuming normal physical activity, grip strength, muscle strength during joint movement.
The period of immobilization was defined as the total number of days during which cast immobilization was maintained. The time to resuming normal physical activity was expressed in days and defined as the period from injury to return to work or school and normal everyday activities.
The rate of bone union was determined based on the percentage of patients who achieved clinical and radiological criteria of bone union. The radiological criteria of bone union were the presence of a minimum of 3 out of 4 consolidated cortical bone layers or trabecular transition between bone fragments on X-rays in 2 views. Clinical bone union was defined as the lack of pathological mobility, pain, or deformity during attempts to perform movements in the wrist area at the fracture site. Nonunion was defined as failure to meet the above criteria for 6 months after the fracture .
The investigators also assessed the number of patients on any analgesics (paracetamol, ibuprofen, non-steroidal anti-inflammatory drugs, tramadol) at the beginning of treatment and at the final follow-up. During regular follow-up visits, patients were asked about their pain intensity using the NRS (Numerical Rating Scale). A period of discontinuation of any pain medication was equivalent to a patient rating their pain level as 0 on the NRS. Time to achieving pain relief was expressed in days and defined as the period from the beginning to end of taking any analgesic drugs.
Complications were assessed based on medical and radiological records. The evaluated complications included nonunion, delayed bone union, fragment displacement, persistent pain, persistent swelling, limited range of motion, vascular damage, nerve damage, the need for revision surgery or repeated reduction and immobilization.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Osteogenon
received an ossein-hydroxyapatite complex
received an ossein-hydroxyapatite complex
Patients in the study group with fractures received an ossein-hydroxyapatite complex (830 mg of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily.
Control
did not receive an ossein-hydroxyapatite complex
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
received an ossein-hydroxyapatite complex
Patients in the study group with fractures received an ossein-hydroxyapatite complex (830 mg of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* a follow-up period of more than 3 months after treatment completion
* complete medical and radiological records
* a written informed consent
* not taking any other medications that could affect bone tissue remodeling
* not taking other medications that interact with Osteogenon
* no other limb pathologies (inflammatory or neurogenic)
* absence of comorbidities that could affect bone union
Exclusion Criteria
* hypersensitivity to the active ingredient or to any of the excipients
* severe renal failure and dialysis therapy
* hypercalcemia
* hypercalciuria
* calcium-based kidney stones or tissue calcifications
* a follow-up period shorter than 3 months after treatment completion
* a lack of informed consent
* a lack of cooperation with the patient
* absent or incomplete medical and radiological records
* taking medications that could affect bone tissue remodeling
* taking medications that may interact with Osteogenon (e.g. thiazide diuretics)
* metabolic disorders
* post-traumatic skeletal deformities
* neuromuscular disorders
* post-inflammatory deformities
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Opole
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Piotr Morasiewicz
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marek Gierlotka, PROF
Role: STUDY_CHAIR
University of Opole
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Clinical Hospital in Opole
Opole, Opole Voivodeship, Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Morasiewicz P, Zaborska M, Sobczak M, Tomczyk L, Leyko P, Bobinski A, Kochanska-Bieri J, Pili D, Kazubski K. The Use of Osteogenon as an Adjunctive Treatment in Lower Leg Fractures. Pharmaceuticals (Basel). 2024 Nov 14;17(11):1531. doi: 10.3390/ph17111531.
Morasiewicz P, Zaborska M, Sobczak M, Tomczyk L, Pili D, Kazubski K, Leyko P. The Use of Ossein-Hydroxyapatite Complex in Conjunction with the Ilizarov Method in the Treatment of Tibial Nonunion. J Clin Med. 2025 May 12;14(10):3353. doi: 10.3390/jcm14103353.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P-2025-004
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
P-2025-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.